69 related articles for article (PubMed ID: 36780229)
1. Efficacious Combination Drug Treatment for Colorectal Cancer That Overcomes Resistance to KRAS G12C Inhibitors.
Matsubara H; Miyoshi H; Kakizaki F; Morimoto T; Kawada K; Yamamoto T; Obama K; Sakai Y; Taketo MM
Mol Cancer Ther; 2023 Apr; 22(4):529-538. PubMed ID: 36780229
[TBL] [Abstract][Full Text] [Related]
2. Targeting
Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
[TBL] [Abstract][Full Text] [Related]
3. Targeting PI3Kα overcomes resistance to KRas
Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
[TBL] [Abstract][Full Text] [Related]
4. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Clinical and Molecular Characterization of
Henry JT; Coker O; Chowdhury S; Shen JP; Morris VK; Dasari A; Raghav K; Nusrat M; Kee B; Parseghian C; Pant S; Jeyakumar N; Zhu L; Nishioka Y; Fogelman D; Wolff RA; Hong D; Overman MJ; Vauthey J; Kopetz S; Johnson B
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250391
[TBL] [Abstract][Full Text] [Related]
6. Activity and resistance to KRAS
Ye W; Lu X; Qiao Y; Ou WB
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract][Full Text] [Related]
8. Concurrent KRAS p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report.
Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
[TBL] [Abstract][Full Text] [Related]
9. KRAS G12C inhibitor combination therapies: current evidence and challenge.
Miyashita H; Kato S; Hong DS
Front Oncol; 2024; 14():1380584. PubMed ID: 38756650
[TBL] [Abstract][Full Text] [Related]
10. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
Wu K; Wu B; Yan K; Ding Q; Miao Z
Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
[TBL] [Abstract][Full Text] [Related]
11. Combined KRAS
Thatikonda V; Lu H; Jurado S; Kostyrko K; Bristow CA; Bosch K; Feng N; Gao S; Gerlach D; Gmachl M; Lieb S; Jeschko A; Machado AA; Marszalek ED; Mahendra M; Jaeger PA; Sorokin A; Strauss S; Trapani F; Kopetz S; Vellano CP; Petronczki M; Kraut N; Heffernan TP; Marszalek JR; Pearson M; Waizenegger I; Hofmann MH
bioRxiv; 2023 Jan; ():. PubMed ID: 36747713
[TBL] [Abstract][Full Text] [Related]
12. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
Boumelha J; Molina-Arcas M; Downward J
Clin Cancer Res; 2023 Dec; 29(24):5012-5020. PubMed ID: 37581538
[TBL] [Abstract][Full Text] [Related]
13. Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine.
Sahin IH; Saridogan T; Ayasun R; Syed MP; Gorantla V; Malhotra M; Thomas R; Rhee J; Zhang J; Hsu D; Singhi AD; Saeed A
JCO Oncol Pract; 2024 May; ():OP2300787. PubMed ID: 38739872
[No Abstract] [Full Text] [Related]
14. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.
Yaeger R; Mezzadra R; Sinopoli J; Bian Y; Marasco M; Kaplun E; Gao Y; Zhao H; Paula ADC; Zhu Y; Perez AC; Chadalavada K; Tse E; Chowdhry S; Bowker S; Chang Q; Qeriqi B; Weigelt B; Nanjangud GJ; Berger MF; Der-Torossian H; Anderes K; Socci ND; Shia J; Riely GJ; Murciano-Goroff YR; Li BT; Christensen JG; Reis-Filho JS; Solit DB; de Stanchina E; Lowe SW; Rosen N; Misale S
Cancer Discov; 2023 Jan; 13(1):41-55. PubMed ID: 36355783
[TBL] [Abstract][Full Text] [Related]
15. Advances in covalent drug discovery.
Boike L; Henning NJ; Nomura DK
Nat Rev Drug Discov; 2022 Dec; 21(12):881-898. PubMed ID: 36008483
[TBL] [Abstract][Full Text] [Related]
16. Transposable element RNA dysregulation in mutant KRAS(G12C) 3D lung cancer spheroids.
Carrillo D; Reggiardo RE; Lim J; Mantalas G; Peddu V; Kim DH
bioRxiv; 2023 Feb; ():. PubMed ID: 36909578
[TBL] [Abstract][Full Text] [Related]
17. Computational insights into KRAS G12C inhibition: exploring possible repurposing of Azacitidine and Ribavirin.
Sharma V; Kumar A; Rawat R; Gulati M; Behl T; Khalid A; Najmi A; Zoghebi K; A Halawi M; Mohan S
J Biomol Struct Dyn; 2024 Feb; ():1-11. PubMed ID: 38415708
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP.
McFall T; Trogdon M; Guizar AC; Langenheim JF; Sisk-Hackworth L; Stites EC
NPJ Precis Oncol; 2022 Nov; 6(1):86. PubMed ID: 36418474
[TBL] [Abstract][Full Text] [Related]
19. Targeting the "Undruggable" Driver Protein, KRAS
Kargbo RB
ACS Med Chem Lett; 2023 Apr; 14(4):365-366. PubMed ID: 37077403
[TBL] [Abstract][Full Text] [Related]
20. Multiscale calculations reveal new insights into the reaction mechanism between KRAS
Yan X; Qu C; Li Q; Zhu L; Tong HHY; Liu H; Ouyang Q; Yao X
Comput Struct Biotechnol J; 2024 Dec; 23():1408-1417. PubMed ID: 38616962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
